Biomarin Pharmaceutical Inc

Latest Results (12.11.2025):

Biomarin Pharmaceutical Inc reported strong financial performance for the second quarter of 2025, marked by robust revenue and earnings growth. The company delivered total revenues of $825 million with double-digit year-over-year increases, strong expansions in GAAP and non-GAAP EPS, and notable profitability improvements. Alongside these results, Biomarin advanced its pipeline with encouraging clinical data for BMN 333 and strategically bolstered its portfolio through the acquisition of Inozyme.

Revenue & Earnings Growth

The second quarter of 2025 saw total revenues reach $825 million, reflecting a 16% year-over-year increase, driven by significant growth with products such as VOXZOGO and enhanced performance of enzyme therapies. GAAP diluted EPS rose to $1.23 (up 124% Y/Y) while non-GAAP diluted EPS reached $1.44 (up 50% Y/Y), contributing to a robust profitability profile. Additionally, GAAP net income and non-GAAP income improvements underline the success of cost management and revenue expansion strategies.

Pipeline & Innovation Highlights

Biomarin demonstrated promising pipeline progress in Q2 2025, where BMN 333 exceeded targeted exposures in healthy volunteer studies, positioning the treatment to enter a pivotal Phase 2/3 study in the first half of 2026 for pediatric achondroplasia. The company continues to advance other clinical programs and presentations, reinforcing its commitment to innovation in treating rare diseases.

Strategic Business Development

In July 2025, Biomarin completed its acquisition of Inozyme, adding BMN 401—a potential first-in-disease treatment for ENPP1 Deficiency—to its Enzyme Therapies portfolio. This strategic move not only enhances Biomarin’s product offerings but also aligns with the company’s broader business development strategy and growth goals.

Future Outlook

Looking ahead, Biomarin is well-positioned for continued momentum in the latter half of 2025 with the anticipated release of pivotal clinical data for various pipeline assets, further expansion in new markets, and ongoing optimization of its operational strategy. The company remains focused on delivering innovative therapies and sustained value for its patients, employees, and shareholders.